Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1474 Views
-
Last post by NHE
-
- 0 Replies
- 809 Views
-
Last post by NHE
-
- 0 Replies
- 2217 Views
-
Last post by frodo
-
- 0 Replies
- 1094 Views
-
Last post by NHE
-
- 1 Replies
- 1016 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1331 Views
-
Last post by frodo
-
- 0 Replies
- 1570 Views
-
Last post by NHE
-
- 0 Replies
- 2029 Views
-
Last post by vesta
-
- 0 Replies
- 1618 Views
-
Last post by frodo